List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 74 studies with search of: "Meningococcal Vaccine"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Condition: Meningococcal Infections
Interventions: Biological: Menactra®;   Biological: Meningococcal vaccine 134612
2 Recruiting Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Condition: Meningococcal Disease
Interventions: Biological: Serogroup B meningococcal Vaccine;   Biological: Serogroup B meningococcal Vaccine;   Biological: Serogroup B meningococcal Vaccine;   Biological: Serogroup B meningococcal Vaccine;   Biological: Serogroup B meningococcal Vaccine;   Biological: Serogroup B meningococcal Vaccine;   Biological: Serogroup B meningococcal Vaccine;   Biological: Serogroup B meningococcal Vaccine
3 Recruiting The Long-Term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults
Condition: Meningococcal Disease
Intervention: Biological: Meningococcal vaccine GSK134612
4 Active, not recruiting Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-Priming With GSK Vaccine 792014
Condition: Invasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y
Interventions: Biological: GSK Biologicals' Meningococcal vaccine GSK134612;   Biological: GSK Biologicals' Hib-meningococcal vaccine GSK 792014;   Biological: Infanrix®;   Biological: ActHIB®;   Biological: Pediarix®
5 Completed Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
Condition: Meningococcal Disease
Interventions: Biological: Meningococcal vaccine GSK134612;   Biological: Mencevax™
6 Completed Primary Study to Demonstrate Non-Inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612
Condition: Meningococcal Serogroup A, C, W-135, Y Diseases
Interventions: Biological: Meningococcal vaccine 134612;   Biological: Twinrix
7 Completed Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects
Condition: Meningococcal Serogroups A, C, W-135 and/or Y Disease
Interventions: Biological: Mencevax™ ACWY;   Biological: Meningococcal vaccine GSK134612
8 Completed Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612
Condition: Healthy Subjects
Interventions: Biological: Meningitec™;   Biological: meningococcal vaccine 134612;   Biological: Mencevax™ ACWY
9 Active, not recruiting Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612
Condition: Meningococcal Serogroups A, C, W-135 and/or Y Disease
Interventions: Biological: Meningococcal vaccine 134612;   Biological: Mencevax™ ACWY
10 Completed Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine
Conditions: Meningococcal Disease;   Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Poliomyelitis;   Haemophilus Influenzae Type b Disease
Interventions: Biological: Infanrix™ hexa;   Biological: Meningitec™;   Biological: Meningococcal vaccine GSK134612
11 Recruiting Co-Administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
Conditions: Meningococcal Disease;   Pneumococcal Disease.
Interventions: Biological: Meningococcal vaccine GSK134612;   Biological: Pneumococcal vaccine GSK1024850A
12 Recruiting The Long-Term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers
Condition: Meningococcal Disease
Intervention: Biological: Meningococcal vaccine GSK134612
13 Completed Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children
Conditions: Meningococcal Serogroup A, C, W-135, Y Diseases;   Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: Meningococcal vaccine GSK134612;   Biological: Meningitec™;   Biological: Priorix-Tetra™
14 Completed Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults
Condition: Meningococcal Infection
Interventions: Biological: Fluarix™;   Biological: Meningococcal vaccine GSK134612;   Biological: Mencevax™ACWY
15 Completed Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children
Condition: Meningococcal Disease
Interventions: Biological: Menjugate;   Biological: GSK Biologicals' meningococcal vaccine GSK134612
16 Recruiting Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB+OMV NZ Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB+OMV NZ Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB+OMV NZ Lot 3);   Biological: Combined DTaP-IPV-HBV-Hib vaccine or Pneumococcal 7-valent Conjugate Vaccine;   Biological: Meningococcal group C oligosaccharide conjugate vaccine
17 Active, not recruiting Immunogenicity and Safety of Menactra Vaccine in Adolescents in Saudi Arabia
Conditions: Neisseria Meningitidis;   Meningococcal Infections
Interventions: Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate;   Biological: Group A, C, W135 and Y polysaccharide meningococcal vaccine;   Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
18 Completed Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: Polysaccharide Diphtheria Conjugate Vaccine;   Biological: Polysaccharide Diphtheria Conjugate Vaccine;   Biological: Polysaccharide Diphtheria Conjugate Vaccine;   Biological: Polysaccharide Diphtheria Conjugate Vaccine
19 Completed Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate;   Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate;   Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate;   Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
20 Completed Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
Conditions: Meningitis;   Meningococcemia;   Pertussis;   Tetanus;   Diphtheria
Interventions: Biological: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.;   Biological: Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.;   Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Hide Download Options
Download Content:




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services